Large size and slow rotation of the trans-Neptunian object (225088) 2007 OR10 discovered from Herschel and K2 observations

We present the first comprehensive thermal and rotational analysis of the second most distant trans-Neptunian object (225088) 2007 OR10. We combined optical light curves provided by the Kepler space telescope -- K2 extended mission and thermal infrared data provided by the Herschel Space Observatory. We found that (225088) 2007 OR10 is likely to be larger and darker than derived by earlier studies: we obtained a diameter of d=1535^{+75}_{-225} km which places (225088) 2007 OR10 in the biggest top three trans-Neptunian objects. The corresponding visual geometric albedo is p_V=0.089^{+0.031}_{-0.009}. The light curve analysis revealed a slow rotation rate of P_rot=44.81+/-0.37 h, superseded by a very few objects only. The most likely light-curve solution is double-peaked with a slight asymmetry, however, we cannot safely rule out the possibility of having a rotation period of P_rot=22.40+/-0.18 h which corresponds to a single-peaked solution. Due to the size and slow rotation, the shape of the object should be a MacLaurin ellipsoid, so the light variation should be caused by surface inhomogeneities. Its newly derived larger diameter also implies larger surface gravity and a more likely retention of volatiles -- CH_4, CO and N_2 -- on the surface.Comment: Accepted for publication in AJ, 8 pages in emulateapj styl

Thermal properties of large main-belt asteroids observed by Herschel PACS

Non-resolved thermal infrared observations enable studies of thermal and physical properties of asteroid surfaces provided the shape and physical models. We used calibration-programme Herschel PACS data (70, 100, 160 $\\mu$m) and state-of-the-art shape models derived from adaptive-optics observations and/or optical light curves to constrain for the first time the thermal inertia of twelve large main-belt asteroids. We also modelled previously well-characterised targets such as (1) Ceres or (4) Vesta as they constitute important benchmarks. Using the scale as a free parameter, most targets required a re-scaling $\\sim$5\\% consistent with what would be expected given the absolute calibration error bars. This constitutes a good cross-validation of the scaled shape models, although some targets required larger re-scaling to reproduce the IR data. We obtained low thermal inertias typical of large main belt asteroids studied before, which continues to give support to the notion that these surfaces are covered by fine-grained insulating regolith. Although the wavelengths at which PACS observed are longwards of the emission peak for main-belt asteroids, they proved to be extremely valuable to constrain size and thermal inertia and not too sensitive to surface roughness. Finally, we also propose a graphical approach to help examine how different values of the exponent used for scaling the thermal inertia as a function of heliocentric distance (i.e. temperature) affect our interpretation of the results

Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial

CKD and type 2 diabetes mellitus interact to increase the risk of major adverse cardiovascular events (i.e., cardiovascular death, nonfatal myocardial infarction, or stroke) and congestive heart failure. A maladaptive epigenetic response may be a cardiovascular risk driver and amenable to modification with apabetalone, a selective modulator of the bromodomain and extraterminal domain transcription system. We examined this question in a prespecified analysis of BETonMACE, a phase 3 trial.BETonMACE was an event-driven, randomized, double-blind, placebo-controlled trial comparing effects of apabetalone versus placebo on major adverse cardiovascular events and heart failure hospitalizations in 2425 participants with type 2 diabetes and a recent acute coronary syndrome, including 288 participants with CKD with eGFR <60 ml/min per 1.73 m2 at baseline. The primary end point in BETonMACE was the time to the first major adverse cardiovascular event, with a secondary end point of time to hospitalization for heart failure.Median follow-up was 27 months (interquartile range, 20-32 months). In participants with CKD, apabetalone compared with placebo was associated with fewer major adverse cardiovascular events (13 events in 124 patients [11%] versus 35 events in 164 patients [21%]; hazard ratio, 0.50; 95% confidence interval, 0.26 to 0.96) and fewer heart failure-related hospitalizations (three hospitalizations in 124 patients [3%] versus 14 hospitalizations in 164 patients [9%]; hazard ratio, 0.48; 95% confidence interval, 0.26 to 0.86). In the non-CKD group, the corresponding hazard ratio values were 0.96 (95% confidence interval, 0.74 to 1.24) for major adverse cardiovascular events, and 0.76 (95% confidence interval, 0.46 to 1.27) for heart failure-related hospitalization. Interaction of CKD on treatment effect was P=0.03 for major adverse cardiovascular events, and P=0.12 for heart failure-related hospitalization. Participants with CKD showed similar numbers of adverse events, regardless of randomization to apabetalone or placebo (119 [73%] versus 88 [71%] patients), and there were fewer serious adverse events (29% versus 43%; P=0.02) in the apabetalone group.Apabetalone may reduce the incidence of major adverse cardiovascular events in patients with CKD and type 2 diabetes who have a high burden of cardiovascular disease

Physical properties of the trans-Neptunian object (38628) Huya from a multi-chord stellar occultation

Context. As part of our international program aimed at obtaining accurate physical properties of trans-Neptunian objects (TNOs), we predicted a stellar occultation by the TNO (38628) Huya of the star Gaia DR2 4352760586390566400 (mG = 11.5 mag) on March 18, 2019. After an extensive observational campaign geared at obtaining the astrometric data, we updated the prediction and found it favorable to central Europe. Therefore, we mobilized half a hundred of professional and amateur astronomers in this region and the occultation was finally detected by 21 telescopes located at 18 sites in Europe and Asia. This places the Huya event among the best ever observed stellar occultation by a TNO in terms of the number of chords. Aims: The aim of our work is to determine an accurate size, shape, and geometric albedo for the TNO (38628) Huya by using the observations obtained from a multi-chord stellar occultation. We also aim to provide constraints on the density and other internal properties of this TNO. Methods: The 21 positive detections of the occultation by Huya allowed us to obtain well-separated chords which permitted us to fit an ellipse for the limb of the body at the moment of the occultation (i.e., the instantaneous limb) with kilometric accuracy. Results: The projected semi-major and minor axes of the best ellipse fit obtained using the occultation data are (a', b') = (217.6 ± 3.5 km, 194.1 ± 6.1 km) with a position angle for the minor axis of P' = 55.2° ± 9.1. From this fit, the projected area-equivalent diameter is 411.0 ± 7.3 km. This diameter is compatible with the equivalent diameter for Huya obtained from radiometric techniques (D = 406 ± 16 km). From this instantaneous limb, we obtained the geometric albedo for Huya (pV = 0.079 ± 0.004) and we explored possible three-dimensional shapes and constraints to the mass density for this TNO. We did not detect the satellite of Huya through this occultation, but the presence of rings or debris around Huya was constrained using the occultation data. We also derived an upper limit for a putative Pluto-like global atmosphere of about psurf = 10 nbar

The multichord stellar occultation on 2019 October 22 by the trans-Neptunian object (84922) 2003 VS2

Context. Stellar occultations have become one of the best techniques to gather information about the physical properties of trans-Neptunian objects (TNOs), which are critical objects for understanding the origin and evolution of our Solar System. Aims: The purpose of this work is to determine, with better accuracy, the physical characteristics of the TNO (84922) 2003 VS2 through the analysis of the multichord stellar occultation on 2019 October 22 and photometric data collected afterward. Methods: We predicted, observed, and analyzed the multichord stellar occultation of the Second Gaia Data Release (Gaia DR2) source 3449076721168026624 (mυ = 14.1 mag) by the plutino object 2003 VS2 on 2019 October 22. We performed aperture photometry on the images collected and derived the times when the star disappeared and reappeared from the observing sites that reported a positive detection. We fit the extremities of such positive chords to an ellipse using a Monte Carlo method. We also carried out photometric observations to derive the rotational light curve amplitude and rotational phase of 2003 VS2 during the stellar occultation. Combining the results and assuming a triaxial shape, we derived the 3D shape of 2003 VS2. Results: Out of the 39 observatories involved in the observational campaign, 12 sites, located in Bulgaria (one), Romania (ten), and Serbia (one), reported a positive detection; this makes it one of the best observed stellar occultations by a TNO so far. Considering the rotational phase of 2003 VS2 during the stellar occultation and the rotational light curve amplitude derived (Am = 0.264 ± 0.017 mag), we obtained a mean area-equivalent diameter of DAeq = 545 ± 13 km and a geometric albedo of 0.134 ± 0.010. By combining the rotational light curve information with the stellar occultation results, we derived the best triaxial shape for 2003 VS2, which has semiaxes a = 339 ± 5 km, b = 235 ± 6 km, and c = 226 ± 8 km. The derived aspect angle of 2003 VS2 is θ = 59° ± 2° or its supplementary θ = 121° ± 2°, depending on the north-pole position of the TNO. The spherical-volume equivalent diameter is DVeq = 524 ± 7 km. If we consider large albedo patches on its surface, the semi-major axis of the ellipsoid could be ~ 10 km smaller. These results are compatible with the previous ones determined from the single-chord 2013 and four-chord 2014 stellar occultations and with the effective diameter and albedo derived from Herschel and Spitzer data. They provide evidence that 2003 VS2's 3D shape is not compatible with a homogeneous triaxial body in hydrostatic equilibrium, but it might be a differentiated body and/or might be sustaining some stress. No secondary features related to rings or material orbiting around 2003 VS2 were detected. The photometric data used to obtain the rotational light curve of (84922) 2003 VS2 are only available at the CDS via anonymous ftp to cdsarc.u-strasbg.fr (ftp://130.79.128.5) or via http://cdsarc.u-strasbg.fr/viz-bin/cat/J/A+A/663/A12

A multicentre, prospective, randomised controlled trial to assess the safety and effectiveness of cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction: the COOL AMI EU Pivotal

Despite primary PCI (PPCI), ST-elevation myocardial infarction (STEMI) can still result in large infarct size (IS). New technology with rapid intravascular cooling showed positive signals for reduction in IS in anterior STEMI.We investigated the effectiveness and safety of rapid systemic intravascular hypothermia as an adjunct to PPCI in conscious patients, with anterior STEMI, without cardiac arrest.Hypothermia was induced using the ZOLL® Proteus™ intravascular cooling system. After randomisation of 111 patients, 58 to hypothermia and 53 to control groups, the study was prematurely discontinued by the sponsor due to inconsistent patient logistics between the groups resulting in significantly longer total ischaemic delay in the hypothermia group (232 vs 188 minutes; p<0.001).There were no differences in angiographic features and PPCI result between the groups. Intravascular temperature at wire crossing was 33.3+0.9°C. Infarct size/left ventricular mass (IS/LV) by cardiac magnetic resonance (CMR) at day 4-6 was 21.3% in the hypothermia group and 20.0% in the control group (p=0.540). Major adverse cardiac events at 30 days increased non-significantly in the hypothermia group (8.6% vs 1.9%; p=0.117) while cardiogenic shock (10.3% vs 0%; p=0.028) and paroxysmal atrial fibrillation (43.1% vs 3.8%; p<0.001) were significantly more frequent in the hypothermia group.The ZOLL Proteus intravascular cooling system reduced temperature to 33.3°C before PPCI in patients with anterior STEMI. Due to inconsistent patient logistics between the groups, this hypothermia protocol resulted in a longer ischaemic delay, did not reduce IS/LV mass and was associated with increased adverse events

Radiofrequency ablation of focal atrial tachycardia: Benefit of electroanatomical mapping over conventional mapping

Background Catheter ablation is a proven therapy of focal atrial tachycardia. However limited information is available about the additional value of electroanatomical over conventional mapping methods for this specific arrhythmia. Methods Consecutive catheter ablation procedures of FAT were analyzed in two cardiology centres. Only conventional mapping was used in 30 of the 60 procedures whereas additionally CARTO mapping was performed in another 30 procedures. Acute, six-month success rate, and procedural data were analyzed. Results Localization of ectopic foci is congruent with previously published data. There was no statistically significant difference between procedure time and fluoroscopy time using additionally CARTO mapping, compared to conventional mapping only. Acute success rate was higher in procedures guided by CARTO mapping than in procedures based on conventional mapping (27/30 vs. 18/30, p = 0.0081). During the 6-month follow-up period there was a better outcome (p = 0.045) in case of CARTO guided procedures (success: 11 cases, partial success: 12 cases, failure: 4 cases) compared to conventional mapping (success: 4 cases, partial success: 18 cases, failure: 7 cases). Conclusions Catheter ablation of focal atrial tachycardias using the CARTO electroanatomical mapping system seems to provide higher acute and 6-month success rate compared to ablation using conventional mapping methods only

Antiinflammatory therapy with canakinumab for atherosclerotic disease

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society